Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9421873 | 0.84 | — | — | |
| SCHEMBL17799153 | 0.74 | — | — | |
| SCHEMBL31164819 | 0.72 | TRIM24 (0.36) | TRIM24TRIM33 | |
| SCHEMBL14163832 | 0.72 | TRIM24 (0.36) | TRIM24TRIM33 | |
| SCHEMBL28527339 | 0.72 | TRIM24 (0.36) | TRIM24TRIM33 | |
| SCHEMBL23630990 | 0.72 | — | — | |
| SCHEMBL6662387 | 0.65 | — | — | |
| SCHEMBL483232 | 0.65 | — | — | |
| SCHEMBL2485364 | 0.65 | TRIM24 (0.65) | TRIM24TRIM33 | |
| SCHEMBL17971494 | 0.64 | TRIM24 (0.54) | TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695324-A1 | BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY | Ocular Therapeutix, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4683964-A2 | POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024215661-A1 | BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY | OCULAR THERAPEUTIX, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024197137-A2 | POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF | OCULAR THERAPEUTIX, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20230405143-A1 | TYROSINE-BASED ANTIBODY CONJUGATES | SYNAFFIX B.V. (NL) | 2023-12-21 | — | — | US | disclosed |
| CN-116744977-A | Tyrosine-based antibody conjugates | 西纳福克斯股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-111118048-B | Use of chimeric phenylalanyl-tRNA synthetases/tRNAs | 浙江大学 | 2022-06-10 | — | — | CN | disclosed |
| US-11220682-B2 | Introducing method of l-dihydroxyphenylalanine in target protein | SOGANG UNIVERSITY RESEARCH & BUSINESS DEVELOPMENT FOUNDATION (KR) | 2022-01-11 | — | — | US | disclosed |
| CN-111118048-A | Use of chimeric phenylalanyl-tRNA synthetases/tRNAs | 浙江大学 | 2020-05-08 | — | — | CN | disclosed |
| US-20190017043-A1 | INTRODUCING METHOD OF L-DIHYDROXYPHENYLALANINE IN TARGET PROTEIN | SOGANG UNIVERSITY RESEARCH & BUSINESS DEVELOPMENT FOUNDATION (KR) | 2019-01-17 | — | — | US | disclosed |
| EP-2974744-A1 | Strain-promoted oxidation controlled cycloaddition with high reaction rate | Stichting Katholieke Universiteit (NL) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405143-A1 | TYROSINE-BASED ANTIBODY CONJUGATES | TYR, TH, TYRO3 | TRIM24 3880/4885TRIM33 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.